Cargando…

Fully human CD19-specific chimeric antigen receptors for T-cell therapy

Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune responses specific for peptides from the murine scFv antigen-binding domain of the CAR can develop in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sommermeyer, Daniel, Hill, Tyler, Shamah, Steven M, Salter, Alexander I, Chen, Yan, Mohler, Kendall M., Riddell, Stanley R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608623/ https://www.ncbi.nlm.nih.gov/pubmed/28202953 http://dx.doi.org/10.1038/leu.2017.57

Ejemplares similares

Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
por: Sommermeyer, Daniel, et al.
Publicado: (2015)

Inclusion of Strep-Tag II in design of antigen receptors for T cell immunotherapy
por: Liu, Lingfeng, et al.
Publicado: (2016)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
por: Berger, S Carolina, et al.
Publicado: (2014)

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape
por: Dai, Zhenyu, et al.
Publicado: (2022)

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)

Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM
por: Shirasu, Naoto, et al.
Publicado: (2012)

Chimeric antigen receptor T-cell therapy for solid tumors
por: Newick, Kheng, et al.
Publicado: (2016)

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
por: Riberdy, Janice M., et al.
Publicado: (2020)

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
por: Hu, Xiaomeng, et al.
Publicado: (2023)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

Corrigendum to “Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM”
por: Shirasu, Naoto, et al.
Publicado: (2015)

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis
por: Bin dokhi, Haifa, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
por: Jena, Bipulendu, et al.
Publicado: (2013)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults
por: Vora, Surabhi B, et al.
Publicado: (2020)

Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
por: Budde, Lihua E., et al.
Publicado: (2013)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
por: Dabiri, Hamed, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
por: Reinhardt, Bryanna, et al.
Publicado: (2023)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
por: Tseng, Hsiang-chi, et al.
Publicado: (2020)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Efficient chimeric antigen receptor targeting of a central epitope of CD22
por: Casey, Nicholas Paul, et al.
Publicado: (2023)

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
por: Feng, Kai-chao, et al.
Publicado: (2017)

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer
por: Yong, Carmen S.M., et al.
Publicado: (2016)

Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy
por: Zhang, Ren-Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hh6vbcbgm3t7uk1qfohjqprkvk